Medidata to Present First-of-its-kind Scientific Innovation at 2017 ASCO Annual Meeting
May 17 2017 - 5:36PM
Business Wire
Medidata (NASDAQ:MDSO), the leading global provider of
cloud-based technology and data analytics for clinical research,
today announced its participation in the 2017 American Society of
Clinical Oncology (ASCO) Annual Meeting, the premier cancer-focused
scientific meeting.
Medidata is the first technology company ever selected by ASCO
to present its scientific innovation to advance clinical research
and further drug development in oncology and beyond.
Working with experts from The University of Texas MD Anderson
Cancer Center, Weill Cornell Medical College and long-time
customer, Roche, Medidata will join more than 30,000 oncology
professionals in Chicago, June 2-6, to discuss state-of-the-art
treatment modalities, new therapies and ongoing controversies in
the field.
Among a pool of more than 5,700 submissions, ASCO selected both
of Medidata’s abstracts:
- “Creating a synthetic control arm from
previous clinical trials: Application to establishing early
endpoints as indicators of overall survival in acute myeloid
leukemia (AML).” The abstract will review Medidata’s scientific
findings from a synthetic control arm (SCA) which was created in
acute myeloid leukemia. Authors from Medidata Data Science and
Roche will present, along with Don Berry, a professor in the
department of biostatistics at The University of Texas MD Anderson
Cancer Center.
Don Berry said: “Synthetic control arms, created out of large
pools of patient data, offer the possibility of early insight
during clinical development programs. Incorporating synthetic
control arms directly into clinical data systems to validate
research decisions is an exciting evolution in the use of
historical control data.”
- “A new unsupervised clustering
algorithm applied to genome-wide profiles of breast cancers in The
Cancer Genome Atlas proper subsets triple-negative samples.”
Medidata’s Clinical Trial Genomics (CTG) algorithm generated a
scientific finding in breast cancer that was accepted for
e-publication. Members from Medidata Data Science and Jason
Mezey, an associate professor at Cornell University and Weill
Cornell Medical College, co-authored this work.
Jason Mezey said: “As we learn more about genomes, more
opportunities will present themselves for better, targeted
therapies. Linking genomic data to the extensive data available
from clinical research systems is providing an unprecedented
opportunity to discover new insights that will impact the clinical
development process.”
David Lee, Medidata’s chief data officer, said: "The two
acceptances at ASCO highlight Medidata's ability to help clients
generate scientific findings faster than ever before. These results
– based on our SCA and CTG offerings – are prime examples of the
unique value customers realize from our unmatched data assets and
cutting-edge data analytics."
Connect with Medidata
- Read our blog, Geeks Talk Clinical
- Tweet this: .@Medidata to present
first-of-its-kind #scientific #innovation at #ASCO17:
http://ow.ly/E36m30bOpgi @ASCO @Roche @MDAndersonNews @Cornell
- Follow us on Twitter: @Medidata
- Find us on LinkedIn
About Medidata
Medidata is reinventing global drug and medical device
development by creating the industry's leading cloud-based
solutions for clinical research. Through our advanced applications
and intelligent data analytics, Medidata helps advance the
scientific goals of life sciences customers worldwide, including
more than 850 global pharmaceutical companies, innovative biotech,
diagnostic and device firms, leading academic medical centers, and
contract research organizations.
The Medidata Clinical Cloud® brings a new level of quality and
efficiency to clinical trials that empower our customers to make
more informed decisions earlier and faster. Our unparalleled
clinical trial data assets provide deep insights that pave the way
for future growth. The Medidata Clinical Cloud is the primary
technology solution powering clinical trials for 18 of the world's
top 25 global pharmaceutical companies and is used by 18 of the top
25 medical device developers—from study design and planning through
execution, management and reporting.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170517006376/en/
MedidataInvestors:Anthony D’Amico, +1
732-767-4331adamico@mdsol.comorMedia:Erik Snider, +1
646-362-2997Medidata Solutionsesnider@mdsol.com
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Apr 2023 to Apr 2024